Study of the effect of vascular endothelial growth factor (VEGF) C(+405)G (rs2010963) single nucleotide polymorphism on the development of esophageal and gastric varices and risk of variceal bleeding in cirrhotic hepatitis C virus (HCV) patients (VEGF) C(+405)G IN esophageal and gastric varices

Aboismail, Ashraf; El-Shazly, Mohamed; Abdallah, Nasser; Elsayed, Eman; Abo-Yossef, Rania

doi:10.1186/s43066-021-00160-1

Egyptian Liver Journal

Table 1 Comparison between the studied groups according to demographic data, complete blood count, creatinine, ALT, AST, ALP, bilirubin, INR, albumin, splenic bipolar diameter, and portal vein diameter by ultrasound abdomen and APRI

From: Study of the effect of vascular endothelial growth factor (VEGF) C(+405)G (rs2010963) single nucleotide polymorphism on the development of esophageal and gastric varices and risk of variceal bleeding in cirrhotic hepatitis C virus (HCV) patients (VEGF) C(+405)G IN esophageal and gastric varices

	Group A (n = 30)	Group B (n = 30)	Group C (n = 30)	p
Sex
Males	19	63.3	18	0.725
Females	11	36.7	12	0.725
Age (years)
Min.‑max.	37.0‑78.0	37.0‑75.0	42.0‑77.0	0.749
Mean ± SD	64.70 ± 8.65	62.90 ± 8.54	64.07 ± 10.51	0.749
Hemoglobin (g/dL)
Min.‑max.	4.50‑12.80	9.50‑14.50	10.10‑17.70	< 0.001*
Mean ± SD	8.81 ± 2.26	12.10 ± 1.34	13.92 ± 1.77	< 0.001*
Sig. bet. grps.	p₁ < 0.001, p₂ < 0.001, p₃ = 0.001*
WBCs (cell/cmm)
Min.‑max.	1.80‑13.0	2.10‑7.45	4.30‑10.40	< 0.001*
Mean ± SD	3.58 ± 2.38	4.23 ± 1.23	7.12 ± 1.37	< 0.001*
Sig. bet. grps.	p₁ = 0.323, p₂ < 0.001, p₃ < 0.001
Platelets (cell/cmm)
Min.‑max.	53.0‑140.0	55.0‑145.0	164.0‑415.0	< 0.001*
Mean ± SD	78.80 ± 26.16	117.73 ± 20.08	275.23 ± 66.26	< 0.001*
Sig. bet. grps.	p₁ = 0.002, p₂ < 0.001, p₃ < 0.001*
Creatinine (mg/dl)
Min.‑max.	0.50‑1.40	0.50‑1.30	0.40‑1.20	0.189
Median (IQR)	1.10 (0.70‑1.20)	0.85 (0.70‑1.10)	0.85 (0.80‑1.10)	0.189
ALT (U/L)
Min.‑max.	18.0‑153.0	19.0‑113.0	11.0‑65.0	< 0.001*
Median (IQR)	55.50 (45.0‑67.0)	35.0 (27.0‑65.0)	18.50 (16.0‑21.0)	< 0.001*
Sig. bet. grps.	p₁ = 0.301, p₂ < 0.001, p₃ < 0.001
AST (U/L)
Min.‑max.	23.0‑112.0	18.0‑118.0	13.0‑43.0	< 0.001*
Median (IQR)	59.50(38.0‑87.0)	44.50(39.0‑78.0)	22.0(17.0‑27.0)	< 0.001*
Sig. bet. grps.	p₁ = 0.411, p₂ < 0.001, p₃ < 0.001
ALP (U/L)
Min.‑max.	103.0‑198.0	78.0‑236.0	44.0‑137.0	< 0.001*
Mean ± SD	158.37 ± 27.76	126.97 ± 39.92	79.17 ± 24.03	< 0.001*
Sig. bet. grps.	p₁ = 0.001, p₂ < 0.001, p₃ < 0.001*
Bilirubin (mg/dL)
Min.‑max.	0.80‑22.0	0.80‑6.70	0.40‑1.20	< 0.001*
Median (IQR)	2.30 (1.90‑3.20)	1.60 (1.30‑2.10)	0.75 (0.60‑0.90)	< 0.001*
Sig. bet. grps.	p₁ = 0.021, p₂ < 0.001, p₃ < 0.001*
INR
Min.‑max.	1.0‑1.40	1.0‑1.40	0.80‑1.30	< 0.001*
Mean ± SD	1.28 ± 0.12	1.14 ± 0.13	1.0 ± 0.10	< 0.001*
Sig. bet. grps.	p₁ < 0.001, p₂ <0 .001, p₃ < 0.001*
Albumin (g/dL)
Min.‑max.	1.70‑3.60	2.20‑4.24	3.50‑5.20	< 0.001*
Median (IQR)	2.70 (2.30‑2.90)	3.05 (2.70‑3.30)	3.90 (3.70‑4.50)	< 0.001*
Sig. bet. grps.	p₁ = 0.001, p₂ < 0.001, p₃ < 0.001*
Splenic span
Min.‑max.	16.0‑23.0	15.0‑19.0	9.0‑12.50	< 0.001*
Mean ± SD	19.0 ± 1.97	16.50 ± 1.18	10.82 ± 0.75	< 0.001*
Sig. bet. grps.	p₁ < 0.001, p₂ < 0.001, p₃ < 0.001*
Portal vein diameter
Min.‑max.	11.0‑19.0	10.0‑16.0	7.0‑12.0	< 0.001*
Mean ± SD	14.63 ± 1.67	13.42 ± 1.32	9.30 ± 1.26	< 0.001*
Sig. bet. grps.	p₁ = 0.004, p₂ < 0.001, p₃ < 0.001*
APRI
Min.‑max.	0.69‑5.28	0.33‑2.32	0.09‑0.35	< 0.001*
Mean ± SD	2.21 ± 1.04	1.21 ± 0.56	0.22 ± 0.08	< 0.001*
Sig. bet. grps.	p₁ < 0.001, p₂ < 0.001, p₃ < 0.001*

Group A, 30 cases of cirrhosis with esophageal varices
Group B, 30 cases of cirrhosis without esophageal varices
Group C 30 healthy individuals as controls
χ² Chi square test^, F F for ANOVA test, IQR interquartile range, p p value for comparing between the studied groups

Back to article page